ライフサイエンスコーパス: intracranial tumor

1 fourth nerve palsy the presenting sign of an intracranial tumor.

2 oma (GBM) remains the most common and lethal intracranial tumor.

3 w and the cells have the ability of tracking intracranial tumor.

4 the CNS intravascularly, NSCs will target an intracranial tumor.

5 P/L-selectins and accumulate selectively in intracranial tumors.

6 immune disorders, systemic malignancies, and intracranial tumors.

7 are very rare, constituting less than 1% of intracranial tumors.

8 ting mice with either visceral metastases or intracranial tumors.

9 cells, and impaired growth and dispersion of intracranial tumors.

10 ival to highly immune resistant, established intracranial tumors.

11 he difficulty in delivering nanoparticles to intracranial tumors.

12 the brain or leaky vasculature of late-stage intracranial tumors.

13 nhanced the survival of mice harboring LN229 intracranial tumors.

14 g the host antitumor immune response against intracranial tumors.

15 glioblastoma are the most common and lethal intracranial tumors.

16 m 2 to 6 h after injection, respectively, in intracranial tumors.

17 esulted in the regression of pre-established intracranial tumors.

18 Gliomas are the most common primary intracranial tumors.

19 activated ex vivo, can eliminate established intracranial tumors.

20 system lymphoma (PCNSL) represents 1% to 3% intracranial tumors.

21 imaging technique in patients irradiated for intracranial tumors.

22 A BPNPs in animals bearing either U87 or RG2 intracranial tumors.

23 wer and constricted blood vessels within the intracranial tumor after drug therapy.

24 stemic toxicity in mice with subcutaneous or intracranial tumors after daily intraperitoneal injectio

25 Previous studies have focused on intracranial tumors, although the skin receives much rad

26 multiforme (GBM) is the most common primary intracranial tumor and despite recent advances in treatm

27 cules for activating immune response against intracranial tumor and the identity of cellular and mole

28 Meningiomas constitute about 34% of primary intracranial tumors and are associated with increased mo

29 Malignant gliomas are the most common intracranial tumors and are considered incurable.

30 ts with neurofibromatosis, account for 8% of intracranial tumors and can only be treated by surgical

31 Pituitary adenomas comprise 10% of intracranial tumors and occur in about 20% of the popula

32 to subcutaneous tumors, lung metastases, and intracranial tumors and offers a solution to many of the

33 rowth was inhibited in both subcutaneous and intracranial tumors, and in the latter instance, treatme

34 Intracranial tumors arising from the subependymal layer

35 the suppressive immunological environment of intracranial tumor bearing mice both systemically and lo

36 )-23, the cells showed protective effects in intracranial tumor-bearing C57BL/6 mice.

37 ds to increased survival of the mice bearing intracranial tumor by decreasing the number of regulator

38 so increased the survival of animals bearing intracranial tumors by 65%.

39 in addition to conventional outcomes such as intracranial tumor control and survival.

40 Advanced 10-day 3-methylcholanthrene 205 intracranial tumors could be cured by the transfer of 15

41 p. EL-4 tumors, but not MCA-205 pulmonary or intracranial tumors, displayed a significant requirement

42 eutic agents that can selectively target the intracranial tumor environment.

43 Experimental intracranial tumors from full-length transfectants showe

44 treatment paradigms for benign and malignant intracranial tumors, functional disorders, and vascular

45 Our data reveal that intracranial tumor growth and angiogenesis is significan

46 tases but nevertheless appears to facilitate intracranial tumor growth.

47 the critical role of VLA-4 in the effective intracranial tumor homing of adoptive-transferred, antig

48 ioblastoma multiforme (GBM), the most common intracranial tumor in adults, is characterized by extens

49 astrocytic malignancies and the most common intracranial tumor in adults.

50 Brain metastases (BM) are the most common intracranial tumor in adults.

51 nsfected dendritic cells (DC-IFN-alpha) into intracranial tumors in mice immunized previously with sy

52 more, the ST6Gal I transfectants produced no intracranial tumors in severe combined immunodeficient m

53 erred to eradicate established pulmonary and intracranial tumors in syngeneic mice, even without coad

54 th histologic evidence that R4009 eradicated intracranial tumors in this model.

55 ablished glioma tumor growth and invasion in intracranial tumors in vivo.

56 The tumoristatic activity against intracranial tumors independent of the blood brain barri

57 ortem examination, FACS-based enumeration of intracranial tumor-infiltrating lymphocytes directly cor

58 Direct Intracranial tumor injection using this reagent resulted

59 The annual incidence of primary intracranial tumors is 7 to 19 cases per 100,000 people.

60 longer than mock-transfected DCs within the intracranial tumor microenvironment, and DC-IFN-alpha-tr

61 In a syngeneic scid mouse intracranial tumor model, recombinant herpes simplex vir

62 Prior to the experiments using intracranial tumor models in nude mice, we modified the

63 llular telephones in a case-control study of intracranial tumors of the nervous system conducted betw

64 t tumors tend to exhibit increased rigidity, intracranial tumors presented as remarkably softer than

65 overexpression promotes GSC self-renewal and intracranial tumor propagation.

66 transferred T cells is sufficient to mediate intracranial tumor regression.

67 rmal human astrocytes into cells that formed intracranial tumors resembling human anaplastic astrocyt

68 -specific shRNA (shMMP-9) treatment of mouse intracranial tumors resulted in elevated expression of m

69 (BPNPs) have high potential for treatment of intracranial tumors since they offer the potential for c

70 al expression of IFN-alpha by DCs within the intracranial tumor site may enhance the clinical efficac

71 as(V12)-transformed human astrocytes reduced intracranial tumor size, in association with reduced tum

72 or activation, to allow for the formation of intracranial tumors strongly resembling p53/pRb pathway-

73 derived from control animals formed smaller intracranial tumors than those derived from beta3 knocko

74 Vestibular schwannoma (VS) is an intracranial tumor that causes significant morbidity, in

75 take and retention in primary and metastatic intracranial tumors treated by conventional radiotherapy

76 Frequent chromosomal aberrations in intracranial tumors were gain of 1q and losses on 6q, 9,

77 Because we observed that s.c., but not intracranial, tumors were infiltrated with CD11c+ DCs, a

78 allowed time to passively accumulate in the intracranial tumors, which served as a proxy for an orth

79 The records of twelve patients with large intracranial tumors who underwent embolization were anal

80 in metastasis is the most commonly occurring intracranial tumor whose incidence seems to be increasin

81 Meningioma is an intracranial tumor with few confirmed risk factors.

82 sidered benign, meningiomas represent 32% of intracranial tumors with three grades of malignancy defi

83 minations were performed in 43 children with intracranial tumors within 24 hours of the completion of

84 4(+) T cells, both established pulmonary and intracranial tumors without coadministration of exogenou

85 Using an intracranial tumor xenograft model, we further demonstra

86 treatment also greatly reduced the volume of intracranial tumor xenografts and increased survival of

87 8 showed enhanced growth as tumorspheres and intracranial tumor xenografts, compared with mock-infect

88 ngly enhances the in vivo growth of s.c. and intracranial tumor xenografts.